MedPath

MICHAEL WAGNER

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma

Phase 1
Recruiting
Conditions
Liposarcoma
Recurrent Liposarcoma
Metastatic Liposarcoma
Unresectable Liposarcoma
MDM2 Gene Amplification
Myxoid Liposarcoma
CIC-Rearranged Sarcoma
Interventions
First Posted Date
2024-05-16
Last Posted Date
2025-06-26
Lead Sponsor
Michael Wagner
Target Recruit Count
24
Registration Number
NCT06414434
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.